IGFBP-1 (placenta protein pp12) ELISA from BIOSERV Diagnostics
(Insulin-like growth factor binding protein-1, placenta protein 12, pp 12, BP-25, a1-pregnancy associated endometrial globulin, alpha1-PEG or a1-PEG, somatomedins-binding protein)
Importance in the clinical routine for: Gynecologists (Early diagnosis of possible pregnancy risks); Pediatricians
EU registration number
DE/CA80/IVD1695
This ready-to-use in-vitro test kit is designed to quantitatively determine the level of IGFBP-1 in human serum in order to diagnose risk pregnancies as well as to prognosticate fetal and postnatal development. Increased concentrations of IGFBP-1 impair both placental growth and fetal growth and may damage the fetus or lead to a miscarriage.
Increased IGFBP-1 concentrations are already detectable 3 to 6 weeks in advance of clinical symptoms such as fetal hypotrophy or hypoxia, pre-eclampsia or intrauterine death of the fetus. Detection of IGFBP-1 levels therefore allows an early beginning of adequate therapies.
Further indications for application of the test
- Diabetes mellitus
- Twin pregnancies
- Functional evaluation of the endometrium
Principle of the test: Solid phase enzyme immunoassay for the quantitative determination of IGFBP-1 concentrations. The BIOSERV Diagnostics IGFBP-1 ELISA is based on the sandwich principle using monoclonal antibodies.
Sample material: serum
To order the IGFBP-1 ELISA please refer to the BIOSERV catalogue number BS-30-10.
For further information please send us an e-mail: info@bioserv-diagnostics.com
More details on IGFBP-1:
The Insulin-like
growth factor binding protein-1 (IGFBP-1) is an acid-stable protein. It
is no placental protein in the true sense, but is
secreted by the endometrium or the decidua, respectively.
IGFBP-1 inhibits
both placental and fetal growth by minimizing
the amount of IGF molecules available in the maternal
organism. By binding
and neutralizing free IGF, unlimited proliferation of the trophoblast into the
decidual endometrium is prevented. High IGFBP-1 concentrations may lead to
retardation, at the worst to the intrauterine death of the fetus and to
miscarriage.
The IGFBP-1 concentration may influence the IGF concentration in serum such that in case of insulin deficiency (Diabetes mellitus type I) serum concentration of IGFBP-1 will be increased while decreased levels occur if insulin is overproduced (Insulinom).
Analysis of IGFBP-1 in amniotic fluid is considered to be the best marker for
detecting fetal
growth disorders. Concentrations of IGFBP-1 in the amniotic fluid are 100 to 500
times increased compared to maternal or fetal serum. By
determining the titer of
IGFBP-1, retardations of the fetus can be detected much earlier than by using
ultrasonography. The highest concentrations of IGFBP-1 in amniotic fluid are
reached in the 2nd trimester and between the 24th and 25th
week of pregnancy. Elevated concentrations
of IGFBP-1 show up either as relatively small
peaks or over a longer period of time. In both cases complications are to be
expected though, e.g., pathohistological alterations of the placenta. Repeated
examinations to monitor high risk pregnancies, primarily between the 24th
and 35th week of pregnancy, are strongly recommended.
Women with twin
pregnancies reveal significantly higher
IGFBP-1 levels, especially within the 10th to 20th week,
compared to single pregnancies. Since multiple pregnancies do not show higher
values than twin pregnancies, the maximum secretory capacity of the endometrium
seems to be obtained in twin pregnancies.
During the stimulation phase, increased levels of IGFBP-1 combined with IGF-1
concentrations are essential in order to evaluate the corpus luteum regulation. Women found to have a polycystic ovary syndrome reveal
normal IGF-1 levels and increased levels of luteinizing hormone and
increased levels of insulin
while the concentration of IGFBP-1 is reduced.
Furthermore, IGFBP-1 is an important indicator for recognizing ruptures of the fetal membrane. In those cases, IGFBP-1 levels of vaginal secretion are drastically increased up to 200-fold. Detection of IGFBP-1 therefore ensures a reliable diagnosis of fetal membrane ruptures with a very high diagnostic specificity.
Trisomy 18 (Edward
syndrome) is also indicated by elevated IGFBP-1 values in combination with a low
concentration of IGF-BP2 during the 1st trimester. In the serum of
non-pregnant women as well as men IGFBP-1 is present only in traces,
approximately 20 ng/ml. Continuous evaluations of IGFBP-1 throughout the day
revealed strong alterations of protein binding values in dependency of the time
of day and food intake. In conclusion patients’ samples should always be taken
at a fixed time, preferably in the morning.
Back to the beginning of this page
For further information please send us an e-mail: info@bioserv-diagnostics.com